Fusobacterium nucleatum Promotes the Growth and Metastasis of Colorectal Cancer by Activating E-Cadherin/Krüppel-Like Factor 4/Integrin α5 Signaling in a Calcium-Dependent Manner

Abstract

Gut microbiota and integrins are known to contribute to colorectal cancer (CRC), but whether they interact has been unclear. Here, we provided evidence that Fusobacterium nucleatum upregulated integrin α5 (ITGA5) in CRC in both human patients and murine models. Knocking down ITGA5 in CRC cells weakened the ability of F. nucleatum to stimulate their malignant characteristics. Fusobacterium nucleatum increased intracellular Ca²⁺ concentration, which in turn promoted interaction between E-cadherin and Krüppel-like factor 4 (KLF4), resulting in KLF4 phosphorylation and translocation in the nucleus, where it induced ITGA5 transcription and activated the downstream signaling. Knocking down E-cadherin or chelating Ca²⁺ with BAPTA-AM antagonized the impact of F. nucleatum on KLF4, whereas knocking down KLF4 or chelating Ca²⁺ antagonized the bacteria’s oncogenic role. Knocking down KLF4 or ITGA5 attenuated F. nucleatum–induced growth of patient-derived organoids, subcutaneous xenografts, and orthotopic tumors, as well as liver metastasis in nude mice. Integrin α5 antibody antagonized the oncogenic role of F. nucleatum in vitro and in vivo. These findings suggest that F. nucleatum promotes the growth and metastasis of CRC by activating E-cadherin/KLF4/integrin α5 signaling in a Ca²⁺-dependent manner.

Keywords

calcium signaling / colorectal cancer / Fusobacterium nucleatum / integrin α5

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.

[2] R. L. Siegel, N. S. Wagle, A. Cercek, R. A. Smith, and A. Jemal, “Colorectal Cancer Statistics, 2023,” CA: A Cancer Journal for Clinicians 73, no. 3 (2023): 233–254.

[3] N. Giannopoulou and C. Constantinou, “Recent Developments in Diagnostic and Prognostic Biomarkers for Colorectal Cancer: A Narrative Review,” Oncology 101, no. 10 (2023): 675–684.

[4] K. Chang, L. Jiang, Y. Sun, and H. Li, “Effect of E-Cadherin on Prognosis of Colorectal Cancer: A Meta-Analysis Update,” Molecular Diagnosis and Therapy 26, no. 4 (2022): 397–409.

[5] A. Matly, J. A. Quinn, D. C. McMillan, J. H. Park, and J. Edwards, “The Relationship Between β-Catenin and Patient Survival in Colorectal Cancer Systematic Review and Meta-Analysis,” Critical Reviews in Oncology/Hematology 163 (2021): 103337.

[6] E. Lee, J. Cheung, and A. B. Bialkowska, “Krüppel-Like Factors 4 and 5 in Colorectal Tumorigenesis,” Cancers (Basel) 15, no. 9 (2023): 2430.

[7] K. Anuja, M. Kar, A. R. Chowdhury, et al., “Role of Telomeric RAP1 in Radiation Sensitivity Modulation and Its Interaction With CSC Marker KLF4 in Colorectal Cancer,” International Journal of Radiation Biology 96, no. 6 (2020): 790–802.

[8] M. T. White and C. L. Sears, “The Microbial Landscape of Colorectal Cancer,” Nature Reviews Microbiology 22, no. 4 (2024): 240–254.

[9] A. D. Kostic, D. Gevers, C. S. Pedamallu, et al., “Genomic Analysis Identifies Association of Fusobacterium With Colorectal Carcinoma,” Genome Research 22, no. 2 (2012): 292–298.

[10] M. R. Rubinstein, X. Wang, W. Liu, et al., “Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via Its FadA Adhesin,” Cell Host & Microbe 14, no. 2 (2013): 195–206.

[11] Y. Yang, W. Weng, J. Peng, et al., “Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21,” Gastroenterology 152, no. 4 (2017): 851–866.

[12] C. Kong, X. Yan, Y. Zhu, et al., “Fusobacterium nucleatum Promotes the Development of Colorectal Cancer by Activating a Cytochrome P450/Epoxyoctadecenoic Acid Axis via TLR4/Keap1/NRF2 Signaling,” Cancer Research 81, no. 17 (2021): 4485–4498.

[13] T. Yu, F. Guo, Y. Yu, et al., “Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy,” Cell 170, no. 3 (2017): 548–563.

[14] X. Wang, Y. Fang, W. Liang, et al., “Fusobacterium nucleatum Facilitates Anti-PD-1 Therapy in Microsatellite Stable Colorectal Cancer,” Cancer Cell 42, no. 10 (2024): 1729–1746.

[15] S. M. Haake, B. L. Rios, A. Pozzi, and R. Zent, “Integrating Integrins With the Hallmarks of Cancer,” Matrix Biology 130 (2024): 20–35.

[16] Y. Gui, X. Deng, N. Li, and L. Zhao, “PRELP Reduce Cell Stiffness and Adhesion to Promote the Growth and Metastasis of Colorectal Cancer Cells by Binding to Integrin α5,” Experimental Cell Research 441, no. 1 (2024): 114151.

[17] Q. Ji, L. Zhou, H. Sui, et al., “Primary Tumors Release ITGBL1-Rich Extracellular Vesicles to Promote Distal Metastatic Tumor Growth Through Fibroblast-Niche Formation,” Nature Communications 11, no. 1 (2020): 1211.

[18] Y. Liu, C. C. Wong, Y. Ding, et al., “Peptostreptococcus Anaerobius Mediates Anti-PD1 Therapy Resistance and Exacerbates Colorectal Cancer via Myeloid-Derived Suppressor Cells in Mice,” Nature Microbiology 9, no. 6 (2024): 1467–1482.

[19] V. Feliu, C. Gomez-Roca, M. Michelas, et al., “Distant Antimetastatic Effect of Enterotropic Colon Cancer-Derived α4β7(+)CD8(+) T Cells,” Science Immunology 8, no. 84 (2023): eadg8841.

[20] C. Li, L. Yu, C. Mai, T. Mu, and Y. Zeng, “KLF4 Down-Regulation Resulting From TLR4 Promotion of ERK1/2 Phosphorylation Underpins Inflammatory Response in Sepsis,” Journal of Cellular and Molecular Medicine 25, no. 4 (2021): 2013–2024.

[21] B. Ma, L. Zhang, Y. Zou, et al., “Reciprocal Regulation of Integrin β4 and KLF4 Promotes Gliomagenesis Through Maintaining Cancer Stem Cell Traits,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 23.

[22] J. A. Pace, R. Bronstein, Y. Guo, et al., “Podocyte-Specific KLF4 Is Required to Maintain Parietal Epithelial Cell Quiescence in the Kidney,” Science Advances 7, no. 36 (2021): eabg6600.

[23] Z. He, J. He, and K. Xie, “KLF4 Transcription Factor in Tumorigenesis,” Cell Death Discovery 9, no. 1 (2023): 118.

[24] M. R. Rubinstein, J. E. Baik, S. M. Lagana, et al., “Fusobacterium nucleatum Promotes Colorectal Cancer by Inducing Wnt/β-Catenin Modulator Annexin A1,” Embo Reports 20, no. 4 (2019): e47638.

[25] S. Shi, Y. Liu, Z. Wang, et al., “Fusobacterium nucleatum Induces Colon Anastomosis Leak by Activating Epithelial Cells to Express MMP9,” Frontiers in Microbiology 13 (2022): 1031882.

[26] M. E. Gingras, B. Masson-Gadais, K. Zaniolo, et al., “Differential Binding of the Transcription Factors Sp1, AP-1, and NFI to the Promoter of the Human alpha5 Integrin Gene Dictates Its Transcriptional Activity,” Investigative Ophthalmology & Visual Science 50, no. 1 (2009): 57–67.

[27] P. Koria and S. T. Andreadis, “KGF Promotes Integrin alpha5 Expression Through CCAAT/Enhancer-Binding Protein-Beta,” American Journal of Physiology Cell Physiology 293, no. 3 (2007): C1020–C1031.

[28] A. Sharma and R. C. Elble, “From Orai to E-Cadherin: Subversion of Calcium Trafficking in Cancer to Drive Proliferation, Anoikis-Resistance, and Metastasis,” Biomedicines 8, no. 6 (2020): 169.

[29] R. Assidicky, U. M. Tokat, I. O. Tarman, et al., “Targeting HIF1-alpha/miR-326/ITGA5 Axis Potentiates Chemotherapy Response in Triple-Negative Breast Cancer,” Breast Cancer Research and Treatment 193, no. 2 (2022): 331–348.

[30] J. Luo, Y. Jiang, L. Wu, et al., “Long Non-Coding RNA ABHD11-AS1 Promotes Colorectal Cancer Progression and Invasion Through Targeting the Integrin Subunit Alpha 5/Focal Adhesion Kinase/Phosphoinositide 3 Kinase/Akt Signaling Pathway,” Aging (Albany NY) 13, no. 16 (2021): 20179–20191.

[31] Y. Gao, D. Bi, R. Xie, et al., “Fusobacterium nucleatum Enhances the Efficacy of PD-L1 Blockade in Colorectal Cancer,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 398.

[32] J. L. Alexander, J. M. Posma, A. Scott, et al., “Pathobionts in the Tumour Microbiota Predict Survival Following Resection for Colorectal Cancer,” Microbiome 11, no. 1 (2023): 100.

[33] S. H. Wong and J. Yu, “Gut Microbiota in Colorectal Cancer: Mechanisms of Action and Clinical Applications,” Nature Reviews Gastroenterology & Hepatology 16, no. 11 (2019): 690–704.

[34] S. S. Jiang, Y. L. Xie, X. Y. Xiao, et al., “Fusobacterium nucleatum-Derived Succinic Acid Induces Tumor Resistance to Immunotherapy in Colorectal Cancer,” Cell Host & Microbe 31, no. 5 (2023): 781–797.

[35] S. Chen, L. Zhang, M. Li, et al., “Fusobacterium nucleatum Reduces METTL3-Mediated M(6)A Modification and Contributes to Colorectal Cancer Metastasis,” Nature Communications 13, no. 1 (2022): 1248.

[36] X. Lu, Q. Xu, Y. Tong, et al., “Long Non-Coding RNA EVADR Induced by Fusobacterium nucleatum Infection Promotes Colorectal Cancer Metastasis,” Cell Reports 40, no. 3 (2022): 111127.

[37] A. Bertocchi, S. Carloni, P. S. Ravenda, et al., “Gut Vascular Barrier Impairment Leads to Intestinal Bacteria Dissemination and Colorectal Cancer Metastasis to Liver,” Cancer Cell 39, no. 5 (2021): 708–724.

[38] L. Lu, R. Xie, R. Wei, et al., “Integrin α5 Subunit Is Required for the Tumor Supportive Role of Fibroblasts in Colorectal Adenocarcinoma and Serves as a Potential Stroma Prognostic Marker,” Molecular Oncology 13, no. 12 (2019): 2697–2714.

[39] M. Yu, S. Chu, B. Fei, X. Fang, and Z. Liu, “O-GlcNAcylation of ITGA5 Facilitates the Occurrence and Development of Colorectal Cancer,” Experimental Cell Research 382, no. 2 (2019): 111464.

[40] S. H. Choi, J. K. Kim, C. T. Chen, et al., “KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer,” Molecular Cancer Research 20, no. 8 (2022): 1305–1319.

[41] X. Xiang, Y. Wang, H. Zhang, et al., “Vasodilator-Stimulated Phosphoprotein Promotes Liver Metastasis of Gastrointestinal Cancer by Activating a β1-Integrin-FAK-YAP1/TAZ Signaling Pathway,” NPJ Precision Oncology 2, no. 1 (2018): 2.

[42] D. Hu, M. Gur, Z. Zhou, et al., “Interplay Between Arginine Methylation and Ubiquitylation Regulates KLF4-Mediated Genome Stability and Carcinogenesis,” Nature Communications 6 (2015): 8419.

[43] P. M. Evans, W. Zhang, X. Chen, et al., “Kruppel-Like Factor 4 Is Acetylated by p300 and Regulates Gene Transcription via Modulation of Histone Acetylation,” Journal of Biological Chemistry 282, no. 47 (2007): 33994–34002.

[44] M. Liu, X. Li, K. Z. Peng, et al., “Subcellular Localization of Klf4 in Non-Small Cell Lung Cancer and Its Clinical Significance,” Biomedicine & Pharmacotherapy 99 (2018): 480–485.

[45] A. Y. Pandya, L. I. Talley, A. R. Frost, et al., “Nuclear Localization of KLF4 Is Associated With an Aggressive Phenotype in Early-Stage Breast Cancer,” Clinical Cancer Research 10, no. 8 (2004): 2709–2719.

[46] E. Burandt, F. Lübbersmeyer, N. Gorbokon, et al., “E-Cadherin Expression in Human Tumors: A Tissue Microarray Study on 10, 851 Tumors,” Biomarker Research 9, no. 1 (2021): 44.

[47] X. Fan, S. Jin, Y. Li, et al., “Genetic and Epigenetic Regulation of E-Cadherin Signaling in Human Hepatocellular Carcinoma,” Cancer Management and Research 11 (2019): 8947–8963.

[48] X. Yang, J. Lou, W. Shan, et al., “Pathogenic Roles of Altered Calcium Channels and Transporters in Colon Tumorogenesis,” Life Sciences 239 (2019): 116909.

[49] W. Mannhardt, K. Beutel, P. Habermehl, M. Knuf, and F. Zepp, “The Interaction of Buccal Mucosal Epithelial Cells With E. coli Bacteria Enhances the Intraepithelial Calcium Flux and the Release of Prostaglandin E2 (PgE2),” International Urogynecology Journal and Pelvic Floor Dysfunction 10, no. 5 (1999): 308–315.

[50] P. Wang, Y. Han, W. Pan, et al., “Tyrosine Phosphatase SHP2 Aggravates Tumor Progression and Glycolysis by Dephosphorylating PKM2 in Gastric Cancer,” MedComm 5, no. 4 (2024): e527.

[51] W. Li, Z. Zhu, M. Chern, et al., “A Natural Allele of a Transcription Factor in Rice Confers Broad-Spectrum Blast Resistance,” Cell 170, no. 1 (2017): 114–126.

[52] M. V. Céspedes, C. Espina, M. A. García-Cabezas, et al., “Orthotopic Microinjection of human Colon Cancer Cells in Nude Mice Induces Tumor Foci in all Clinically Relevant Metastatic Sites,” American Journal of Pathology 170, no. 3 (2007): 1077–1085.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.